TNFSF10 and melanoma: When examining the effect of the combination therapy on clonal survival of these melanoma cells, we observed that TRAIL–CDK9i entirely repressed the capacity of clonal outgrowth in both, therapy-sensitive and -resistant melanoma cells (Fig. 4h-j).